SK20099A3 - Treatment of upper airway allergic responses with a combination of histamine receptor antagonists - Google Patents
Treatment of upper airway allergic responses with a combination of histamine receptor antagonists Download PDFInfo
- Publication number
- SK20099A3 SK20099A3 SK200-99A SK20099A SK20099A3 SK 20099 A3 SK20099 A3 SK 20099A3 SK 20099 A SK20099 A SK 20099A SK 20099 A3 SK20099 A3 SK 20099A3
- Authority
- SK
- Slovakia
- Prior art keywords
- receptor antagonist
- receptor
- treatment
- receptor antagonists
- histamine
- Prior art date
Links
- 208000026935 allergic disease Diseases 0.000 title description 5
- 229940122236 Histamine receptor antagonist Drugs 0.000 title 1
- 239000003395 histamine H3 receptor antagonist Substances 0.000 claims abstract description 17
- 208000024891 symptom Diseases 0.000 claims abstract description 17
- 239000000938 histamine H1 antagonist Substances 0.000 claims abstract description 16
- 206010039083 rhinitis Diseases 0.000 claims abstract description 9
- 230000001387 anti-histamine Effects 0.000 claims abstract description 8
- 239000002552 dosage form Substances 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims description 16
- 239000002464 receptor antagonist Substances 0.000 claims description 13
- 229940044551 receptor antagonist Drugs 0.000 claims description 13
- 241000700199 Cavia porcellus Species 0.000 claims description 5
- 210000004556 brain Anatomy 0.000 claims description 5
- 230000017531 blood circulation Effects 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 2
- 210000002850 nasal mucosa Anatomy 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 27
- 239000000739 antihistaminic agent Substances 0.000 abstract description 8
- 229940124056 Histamine H1 receptor antagonist Drugs 0.000 abstract 1
- 229940115480 Histamine H3 receptor antagonist Drugs 0.000 abstract 1
- 239000000133 nasal decongestant Substances 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 28
- 102000005962 receptors Human genes 0.000 description 21
- 108020003175 receptors Proteins 0.000 description 21
- 229960001340 histamine Drugs 0.000 description 14
- 239000000126 substance Substances 0.000 description 13
- 206010028735 Nasal congestion Diseases 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- QKDDJDBFONZGBW-UHFFFAOYSA-N N-Cyclohexy-4-(imidazol-4-yl)-1-piperidinecarbothioamide Chemical compound C1CC(C=2NC=NC=2)CCN1C(=S)NC1CCCCC1 QKDDJDBFONZGBW-UHFFFAOYSA-N 0.000 description 11
- 229960003291 chlorphenamine Drugs 0.000 description 11
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 11
- UCAIEVHKDLMIFL-UHFFFAOYSA-N clobenpropit Chemical compound C1=CC(Cl)=CC=C1CNC(=N)SCCCC1=CNC=N1 UCAIEVHKDLMIFL-UHFFFAOYSA-N 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 7
- 239000005557 antagonist Substances 0.000 description 7
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 7
- 229960000395 phenylpropanolamine Drugs 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 206010020751 Hypersensitivity Diseases 0.000 description 6
- 206010061298 Mucosal haemorrhage Diseases 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 208000027744 congestion Diseases 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 206010039085 Rhinitis allergic Diseases 0.000 description 5
- 201000010105 allergic rhinitis Diseases 0.000 description 5
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- MFMMJKGZEGTTSV-UHFFFAOYSA-N Verongamine Natural products C1=C(Br)C(OC)=CC=C1CC(=NO)C(=O)NCCC1=CN=CN1 MFMMJKGZEGTTSV-UHFFFAOYSA-N 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 229960003088 loratadine Drugs 0.000 description 4
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000001603 reducing effect Effects 0.000 description 4
- 206010041232 sneezing Diseases 0.000 description 4
- 230000002889 sympathetic effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- MFMMJKGZEGTTSV-DEDYPNTBSA-N verongamine Chemical compound C1=C(Br)C(OC)=CC=C1C\C(=N/O)C(=O)NCCC1=CNC=N1 MFMMJKGZEGTTSV-DEDYPNTBSA-N 0.000 description 4
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 230000000172 allergic effect Effects 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 210000000748 cardiovascular system Anatomy 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 229960001271 desloratadine Drugs 0.000 description 3
- 210000003630 histaminocyte Anatomy 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229960002748 norepinephrine Drugs 0.000 description 3
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241000700198 Cavia Species 0.000 description 2
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 208000030961 allergic reaction Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 229940046978 chlorpheniramine maleate Drugs 0.000 description 2
- -1 clemastim Chemical compound 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 210000001640 nerve ending Anatomy 0.000 description 2
- 210000001331 nose Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 238000007790 scraping Methods 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- UIKROCXWUNQSPJ-VIFPVBQESA-N (-)-cotinine Chemical compound C1CC(=O)N(C)[C@@H]1C1=CC=CN=C1 UIKROCXWUNQSPJ-VIFPVBQESA-N 0.000 description 1
- SFOVDSLXFUGAIV-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]-n-piperidin-4-ylbenzimidazol-2-amine Chemical compound C1=CC(F)=CC=C1CN1C2=CC=CC=C2N=C1NC1CCNCC1 SFOVDSLXFUGAIV-UHFFFAOYSA-N 0.000 description 1
- BGSRSMTXDSZDMZ-UHFFFAOYSA-N 2-[2-(1h-imidazol-5-yl)ethylsulfanyl]-5-nitropyridine Chemical compound N1=CC([N+](=O)[O-])=CC=C1SCCC1=CNC=N1 BGSRSMTXDSZDMZ-UHFFFAOYSA-N 0.000 description 1
- VKPJPAPCRZIUMA-UHFFFAOYSA-N 2-[3-(1h-imidazol-5-yl)propyl]guanidine Chemical compound NC(N)=NCCCC1=CN=CN1 VKPJPAPCRZIUMA-UHFFFAOYSA-N 0.000 description 1
- CPOUJACQGWJJQB-UHFFFAOYSA-N 3-[(4-chlorophenyl)methyl]-5-[2-(1h-imidazol-5-yl)ethyl]-1,2,4-oxadiazole Chemical compound C1=CC(Cl)=CC=C1CC1=NOC(CCC=2N=CNC=2)=N1 CPOUJACQGWJJQB-UHFFFAOYSA-N 0.000 description 1
- VNIOQSAWKLOGLY-UHFFFAOYSA-N 3-[(5-methylfuran-2-yl)methyl]-n-piperidin-4-ylimidazo[4,5-b]pyridin-2-amine Chemical compound O1C(C)=CC=C1CN1C2=NC=CC=C2N=C1NC1CCNCC1 VNIOQSAWKLOGLY-UHFFFAOYSA-N 0.000 description 1
- LWQDMFJSQPGBSO-UHFFFAOYSA-N 3-amino-1-(1h-imidazol-5-yl)propan-1-one Chemical compound NCCC(=O)C1=CNC=N1 LWQDMFJSQPGBSO-UHFFFAOYSA-N 0.000 description 1
- YTCGNPGLMAECND-UHFFFAOYSA-N 5-cyclohexyl-1-[4-(1h-imidazol-5-yl)piperidin-1-yl]pentan-1-one Chemical compound C1CC(C=2N=CNC=2)CCN1C(=O)CCCCC1CCCCC1 YTCGNPGLMAECND-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- UIKROCXWUNQSPJ-UHFFFAOYSA-N Cotinine Natural products C1CC(=O)N(C)C1C1=CC=CN=C1 UIKROCXWUNQSPJ-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 102000003834 Histamine H1 Receptors Human genes 0.000 description 1
- 108090000110 Histamine H1 Receptors Proteins 0.000 description 1
- 102000000543 Histamine Receptors Human genes 0.000 description 1
- 108010002059 Histamine Receptors Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 description 1
- HOKDBMAJZXIPGC-UHFFFAOYSA-N Mequitazine Chemical compound C12=CC=CC=C2SC2=CC=CC=C2N1CC1C(CC2)CCN2C1 HOKDBMAJZXIPGC-UHFFFAOYSA-N 0.000 description 1
- UEQUQVLFIPOEMF-UHFFFAOYSA-N Mianserin Chemical compound C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 UEQUQVLFIPOEMF-UHFFFAOYSA-N 0.000 description 1
- FHQDWPCFSJMNCT-UHFFFAOYSA-N N(tele)-methylhistamine Chemical compound CN1C=NC(CCN)=C1 FHQDWPCFSJMNCT-UHFFFAOYSA-N 0.000 description 1
- JCMWSVNNSPUNER-UHFFFAOYSA-N N,O-dimethyltyramine Chemical compound CNCCC1=CC=C(OC)C=C1 JCMWSVNNSPUNER-UHFFFAOYSA-N 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- DYWNLSQWJMTVGJ-KUSKTZOESA-N Phenylpropanolamine hydrochloride Chemical compound Cl.C[C@H](N)[C@H](O)C1=CC=CC=C1 DYWNLSQWJMTVGJ-KUSKTZOESA-N 0.000 description 1
- 208000036284 Rhinitis seasonal Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- UFLGIAIHIAPJJC-UHFFFAOYSA-N Tripelennamine Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CC=C1 UFLGIAIHIAPJJC-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 229960003792 acrivastine Drugs 0.000 description 1
- PWACSDKDOHSSQD-IUTFFREVSA-N acrivastine Chemical compound C1=CC(C)=CC=C1C(\C=1N=C(\C=C\C(O)=O)C=CC=1)=C/CN1CCCC1 PWACSDKDOHSSQD-IUTFFREVSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- GXDALQBWZGODGZ-UHFFFAOYSA-N astemizole Chemical compound C1=CC(OC)=CC=C1CCN1CCC(NC=2N(C3=CC=CC=C3N=2)CC=2C=CC(F)=CC=2)CC1 GXDALQBWZGODGZ-UHFFFAOYSA-N 0.000 description 1
- 229960000383 azatadine Drugs 0.000 description 1
- SEBMTIQKRHYNIT-UHFFFAOYSA-N azatadine Chemical compound C1CN(C)CCC1=C1C2=NC=CC=C2CCC2=CC=CC=C21 SEBMTIQKRHYNIT-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229960000725 brompheniramine Drugs 0.000 description 1
- ZDIGNSYAACHWNL-UHFFFAOYSA-N brompheniramine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Br)C=C1 ZDIGNSYAACHWNL-UHFFFAOYSA-N 0.000 description 1
- RIMGDBZXWSGBQN-UHFFFAOYSA-N burimamide Chemical compound CNC(=S)NCCCCC1=CN=C[N]1 RIMGDBZXWSGBQN-UHFFFAOYSA-N 0.000 description 1
- 229960000428 carbinoxamine Drugs 0.000 description 1
- OJFSXZCBGQGRNV-UHFFFAOYSA-N carbinoxamine Chemical compound C=1C=CC=NC=1C(OCCN(C)C)C1=CC=C(Cl)C=C1 OJFSXZCBGQGRNV-UHFFFAOYSA-N 0.000 description 1
- 229950010123 carebastine Drugs 0.000 description 1
- XGHOVGYJHWQGCC-UHFFFAOYSA-N carebastine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(=O)CCCN1CCC(OC(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 XGHOVGYJHWQGCC-UHFFFAOYSA-N 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
- 229960004170 clozapine Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000001609 comparable effect Effects 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 230000009989 contractile response Effects 0.000 description 1
- 229950006073 cotinine Drugs 0.000 description 1
- 229960003564 cyclizine Drugs 0.000 description 1
- UVKZSORBKUEBAZ-UHFFFAOYSA-N cyclizine Chemical compound C1CN(C)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 UVKZSORBKUEBAZ-UHFFFAOYSA-N 0.000 description 1
- 229960001140 cyproheptadine Drugs 0.000 description 1
- JJCFRYNCJDLXIK-UHFFFAOYSA-N cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- HCFDWZZGGLSKEP-UHFFFAOYSA-N doxylamine Chemical compound C=1C=CC=NC=1C(C)(OCCN(C)C)C1=CC=CC=C1 HCFDWZZGGLSKEP-UHFFFAOYSA-N 0.000 description 1
- 229960005178 doxylamine Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002169 ethanolamines Chemical class 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- ICLWTJIMXVISSR-UHFFFAOYSA-N gallamine Chemical compound CCN(CC)CCOC1=CC=CC(OCCN(CC)CC)=C1OCCN(CC)CC ICLWTJIMXVISSR-UHFFFAOYSA-N 0.000 description 1
- 229960003054 gallamine Drugs 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- MZCJWLAXZRFUPI-UHFFFAOYSA-N impentamine Chemical compound NCCCCCC1=CN=CN1 MZCJWLAXZRFUPI-UHFFFAOYSA-N 0.000 description 1
- MURRAGMMNAYLNA-UHFFFAOYSA-N impromidine Chemical compound N1C=NC(CSCCNC(N)=NCCCC=2NC=NC=2)=C1C MURRAGMMNAYLNA-UHFFFAOYSA-N 0.000 description 1
- 229950005073 impromidine Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000030214 innervation Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 208000012866 low blood pressure Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000000350 mc(t) Anatomy 0.000 description 1
- 229960001474 meclozine Drugs 0.000 description 1
- 229960000582 mepyramine Drugs 0.000 description 1
- YECBIJXISLIIDS-UHFFFAOYSA-N mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 description 1
- 229960005042 mequitazine Drugs 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 229960003955 mianserin Drugs 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 230000007433 nerve pathway Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 229950009470 noberastine Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000002990 phenothiazines Chemical class 0.000 description 1
- 229960002305 phenylpropanolamine hydrochloride Drugs 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229960003910 promethazine Drugs 0.000 description 1
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 1
- 229960003908 pseudoephedrine Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000004739 secretory vesicle Anatomy 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229950008023 sopromidine Drugs 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- 229960000351 terfenadine Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 229960003223 tripelennamine Drugs 0.000 description 1
- 229960001128 triprolidine Drugs 0.000 description 1
- CBEQULMOCCWAQT-WOJGMQOQSA-N triprolidine Chemical compound C1=CC(C)=CC=C1C(\C=1N=CC=CC=1)=C/CN1CCCC1 CBEQULMOCCWAQT-WOJGMQOQSA-N 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68995196A | 1996-08-16 | 1996-08-16 | |
| PCT/US1997/013903 WO1998006394A1 (fr) | 1996-08-16 | 1997-08-13 | Traitement des reponses allergiques des voies aeriennes superieures a l'aide d'une combinaison d'antagonistes des recepteurs de l'histamine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK20099A3 true SK20099A3 (en) | 2000-08-14 |
Family
ID=24770500
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK200-99A SK20099A3 (en) | 1996-08-16 | 1997-08-13 | Treatment of upper airway allergic responses with a combination of histamine receptor antagonists |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP0920315B1 (fr) |
| JP (2) | JP3638289B2 (fr) |
| KR (1) | KR20000029975A (fr) |
| CN (1) | CN1152682C (fr) |
| AR (1) | AR008293A1 (fr) |
| AT (1) | ATE314071T1 (fr) |
| AU (1) | AU722040B2 (fr) |
| BR (1) | BR9711149A (fr) |
| CA (1) | CA2263163A1 (fr) |
| CO (1) | CO4910138A1 (fr) |
| CZ (1) | CZ43299A3 (fr) |
| DE (1) | DE69734984D1 (fr) |
| HU (1) | HUP9904362A3 (fr) |
| ID (1) | ID17871A (fr) |
| IL (1) | IL128573A0 (fr) |
| MY (1) | MY116130A (fr) |
| NO (1) | NO990706L (fr) |
| NZ (1) | NZ334063A (fr) |
| PE (1) | PE100298A1 (fr) |
| PL (1) | PL191073B1 (fr) |
| SK (1) | SK20099A3 (fr) |
| TR (1) | TR199900326T2 (fr) |
| TW (2) | TWI221768B (fr) |
| WO (1) | WO1998006394A1 (fr) |
| ZA (1) | ZA977263B (fr) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2284705A1 (fr) * | 1997-03-26 | 1998-10-01 | Sepracor Inc. | Formulations chimiquement et thermiquement stables de norastemizole |
| PT998272E (pt) * | 1997-08-26 | 2003-09-30 | Aventis Pharma Inc | Composicao farmaceutica para combinacao do descongestionante piperidinoalcanol |
| JP2001522835A (ja) * | 1997-11-07 | 2001-11-20 | シェーリング コーポレイション | フェニル−アルキル−イミダゾール型のｈ３レセプターリガンド |
| US5990147A (en) * | 1997-11-07 | 1999-11-23 | Schering Corporation | H3 receptor ligands of the phenyl-alkyl-imidazoles type |
| US6034251A (en) * | 1997-11-07 | 2000-03-07 | Schering Corporation | Phenyl-alkyl-imidazoles |
| HUP0102662A3 (en) * | 1997-11-07 | 2003-01-28 | Schering Corp | Imidazoylalkyl substituted with a five, six or seven membered heterocyclic ring containing one nitrogen atom |
| JP2001522836A (ja) * | 1997-11-07 | 2001-11-20 | シェーリング コーポレイション | Ｈ３レセプターアンタゴニストとしてのフェニル−アルキル−イミダゾール |
| US6384038B1 (en) * | 1998-04-14 | 2002-05-07 | Sepracor Inc. | Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants |
| JP2002527381A (ja) * | 1998-10-09 | 2002-08-27 | シェーリング コーポレイション | アレルギー性疾患を処置するための組成物および方法 |
| US6100279A (en) * | 1998-11-05 | 2000-08-08 | Schering Corporation | Imidazoylalkyl substituted with a five, six or seven membered heterocyclic ring containing one nitrogen atom |
| AU7589700A (en) * | 1999-09-22 | 2001-04-24 | Schering Corporation | Treating allergic and inflammatory conditions |
| JP2003521515A (ja) * | 2000-02-03 | 2003-07-15 | シェーリング コーポレイション | アレルギー状態および炎症状態の処置 |
| PE20020507A1 (es) | 2000-10-17 | 2002-06-25 | Schering Corp | Compuestos no-imidazoles como antagonistas del receptor histamina h3 |
| GB2373186A (en) * | 2001-02-23 | 2002-09-18 | Astrazeneca Ab | Pharmaceutical combinations of a CCR3 antagonist and a compound which is usefulreatment of asthma, allergic disease or inflammation |
| CN1298715C (zh) | 2001-03-13 | 2007-02-07 | 先灵公司 | 作为组胺h3拮抗剂的非咪唑化合物 |
| PE20040464A1 (es) | 2002-04-18 | 2004-07-24 | Schering Corp | Benzimidazolonas sustituidas y derivados como antagonistas de histamina h3 |
| US7105505B2 (en) | 2002-04-18 | 2006-09-12 | Schering Corporation | Benzimidazole derivatives useful as histamine H3 antagonists |
| PT1539742E (pt) | 2002-06-24 | 2007-01-31 | Schering Corp | Derivados de índole úteis como antagonistas h3 de histamina |
| WO2004066960A2 (fr) * | 2003-01-28 | 2004-08-12 | Schering Corporation | Combinaison d'antagonistes des recepteurs h1, h3 et h4 en vue du traitement d'inflammations pulmonaires allergiques et non allergiques, de congestions et de rhinites allergiques |
| EP1902046B1 (fr) | 2005-06-20 | 2009-12-02 | Schering Corporation | Dérivés de la pipéridine utiles comme antagonistes du récepteur h3 de l'histamine |
| WO2010027567A2 (fr) | 2008-07-23 | 2010-03-11 | Schering Corporation | Dérivés spirocycliques tricycliques et leurs procédés d’utilisation |
| EP2350048A2 (fr) | 2008-10-16 | 2011-08-03 | Schering Corporation | Dérivés d'azine et leurs méthodes d'utilisation |
| EP2379565A1 (fr) | 2008-12-19 | 2011-10-26 | Schering Corporation | Dérivés de pipéridine et de pipérazine et leurs méthodes d'utilisation |
| US8283360B2 (en) | 2008-12-19 | 2012-10-09 | Merck Sharp & Dohme Corp. | Bicyclic heterocyclic derivatives and methods of use thereof |
| US8569273B2 (en) | 2009-03-17 | 2013-10-29 | Aciex Therapeutics, Inc. | Ophthalmic formulations of cetirizine and methods of use |
| ES2910374T3 (es) | 2009-03-17 | 2022-05-12 | Nicox Ophthalmics Inc | Formulaciones oftálmicas de cetirizina y procedimientos de uso |
| CN107582551A (zh) * | 2009-05-14 | 2018-01-16 | 总医院公司 | 治疗退化性及缺血性疾病的方法和组合物 |
| US8759357B2 (en) | 2009-10-08 | 2014-06-24 | Merck Sharp & Dohme Corp. | Inhibitors of fatty acid binding protein (FABP) |
| WO2013151982A1 (fr) | 2012-04-03 | 2013-10-10 | Arena Pharmaceuticals, Inc. | Méthodes et composés utiles pour traiter le prurit, et procédés d'identification desdits composés |
| RU2685277C1 (ru) * | 2018-05-24 | 2019-04-17 | Общество с ограниченной ответственностью "Фарминтерпрайсез Аллерджи" | Применение бисамидного производного малоновой кислоты для лечения аллергических и других заболеваний человека и животных |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU201683B (en) * | 1987-08-04 | 1990-12-28 | Biogal Gyogyszergyar | Process for producing pharmaceutical compositions for promoting healing of wounds |
| US5019591A (en) * | 1989-02-17 | 1991-05-28 | Pennsylvania Research Corporation | Method for treating retinopathy and other small vessel disorders associated with diabetes |
| GB9303210D0 (en) * | 1993-02-17 | 1993-03-31 | Univ Manitoba | Cancer treatment |
-
1997
- 1997-08-13 MY MYPI97003708A patent/MY116130A/en unknown
- 1997-08-13 CN CNB971987130A patent/CN1152682C/zh not_active Expired - Fee Related
- 1997-08-13 CZ CZ99432A patent/CZ43299A3/cs unknown
- 1997-08-13 TW TW086111627A patent/TWI221768B/zh not_active IP Right Cessation
- 1997-08-13 HU HU9904362A patent/HUP9904362A3/hu unknown
- 1997-08-13 DE DE69734984T patent/DE69734984D1/de not_active Expired - Lifetime
- 1997-08-13 ZA ZA9707263A patent/ZA977263B/xx unknown
- 1997-08-13 BR BR9711149A patent/BR9711149A/pt not_active Application Discontinuation
- 1997-08-13 AT AT97937153T patent/ATE314071T1/de not_active IP Right Cessation
- 1997-08-13 KR KR1019997001226A patent/KR20000029975A/ko not_active Abandoned
- 1997-08-13 PL PL331617A patent/PL191073B1/pl not_active IP Right Cessation
- 1997-08-13 AU AU39733/97A patent/AU722040B2/en not_active Ceased
- 1997-08-13 NZ NZ334063A patent/NZ334063A/xx unknown
- 1997-08-13 AR ARP970103693A patent/AR008293A1/es unknown
- 1997-08-13 EP EP97937153A patent/EP0920315B1/fr not_active Expired - Lifetime
- 1997-08-13 JP JP50985998A patent/JP3638289B2/ja not_active Expired - Fee Related
- 1997-08-13 TW TW093112764A patent/TW200427450A/zh unknown
- 1997-08-13 WO PCT/US1997/013903 patent/WO1998006394A1/fr not_active Ceased
- 1997-08-13 CA CA002263163A patent/CA2263163A1/fr not_active Abandoned
- 1997-08-13 PE PE1997000705A patent/PE100298A1/es not_active Application Discontinuation
- 1997-08-13 IL IL12857397A patent/IL128573A0/xx unknown
- 1997-08-13 SK SK200-99A patent/SK20099A3/sk unknown
- 1997-08-13 TR TR1999/00326T patent/TR199900326T2/xx unknown
- 1997-08-14 CO CO97046887A patent/CO4910138A1/es unknown
- 1997-08-14 ID IDP972837A patent/ID17871A/id unknown
-
1999
- 1999-02-15 NO NO990706A patent/NO990706L/no unknown
-
2002
- 2002-07-30 JP JP2002222138A patent/JP2003095979A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CN1233179A (zh) | 1999-10-27 |
| CN1152682C (zh) | 2004-06-09 |
| NO990706D0 (no) | 1999-02-15 |
| MY116130A (en) | 2003-11-28 |
| NZ334063A (en) | 2000-09-29 |
| TWI221768B (en) | 2004-10-11 |
| JP2003095979A (ja) | 2003-04-03 |
| PE100298A1 (es) | 1999-01-11 |
| ATE314071T1 (de) | 2006-01-15 |
| CO4910138A1 (es) | 2000-04-24 |
| EP0920315B1 (fr) | 2005-12-28 |
| NO990706L (no) | 1999-02-15 |
| WO1998006394A1 (fr) | 1998-02-19 |
| HUP9904362A2 (hu) | 2000-11-28 |
| BR9711149A (pt) | 1999-08-17 |
| ID17871A (id) | 1998-02-05 |
| PL331617A1 (en) | 1999-08-02 |
| HUP9904362A3 (en) | 2000-12-28 |
| IL128573A0 (en) | 2000-01-31 |
| AU722040B2 (en) | 2000-07-20 |
| AR008293A1 (es) | 1999-12-29 |
| CA2263163A1 (fr) | 1998-02-19 |
| AU3973397A (en) | 1998-03-06 |
| KR20000029975A (ko) | 2000-05-25 |
| EP0920315A1 (fr) | 1999-06-09 |
| CZ43299A3 (cs) | 1999-07-14 |
| JP2000505094A (ja) | 2000-04-25 |
| ZA977263B (en) | 1998-02-16 |
| JP3638289B2 (ja) | 2005-04-13 |
| PL191073B1 (pl) | 2006-03-31 |
| TW200427450A (en) | 2004-12-16 |
| DE69734984D1 (de) | 2006-02-02 |
| TR199900326T2 (xx) | 1999-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK20099A3 (en) | Treatment of upper airway allergic responses with a combination of histamine receptor antagonists | |
| US5869479A (en) | Treatment of upper airway allergic responses | |
| US6936601B2 (en) | Compositions for treating pain | |
| DE69316023T2 (de) | Stabile zusammensetzung für eine orale dosis mit verlängerter freisetzung | |
| EP1755561B1 (fr) | Comprime multicouche comprenant des medicaments anti-inflammatoires non steroidiens, des decongestionnants et des antihistaminiques non sedatifs | |
| US7834056B2 (en) | Pharmaceutical composition for gout | |
| JPH08501561A (ja) | （−）セチリジンを用いたアレルギー疾患の治療のための組成物 | |
| EP3813831B1 (fr) | Compositions à libération prolongée comprenant du trihexyphénidyle | |
| DE2823174A1 (de) | Arzneimittel fuer die prophylaktische behandlung postoperativer tiefer venenthrombose | |
| JP2001515475A (ja) | 尿失禁、動揺病及びめまいの治療薬の製造のためのデスカルボエトキシロラタジンの使用 | |
| US20220323429A1 (en) | Pimavanserin for treating neurodegenerative diseases | |
| CZ150999A3 (cs) | Farmaceutický prostředek pro léčbu astmatu obsahující loratadin a dekongestant | |
| JP5680412B2 (ja) | レオヌリンの使用およびその組成物 | |
| US20080311196A1 (en) | All Day Rhinitic Condition Treatment Regimen | |
| US20030216423A1 (en) | Stable liquid and solid formulations | |
| DE10392164T5 (de) | Oral verabreichbare pharmazeutische Formulierung | |
| JP7745086B2 (ja) | ＡＲＮｉとカルシウムイオンアンタゴニストとの医薬組成物および応用 | |
| EP1810678A1 (fr) | Utilisation de morphine et naloxone pour la substitution de médicaments | |
| CN109646438A (zh) | 去甲乌药碱或其盐酸盐在制备治疗鼻炎药物中的应用 | |
| JP2001511159A (ja) | オキシムを含むシナプス機能障害の処置用医薬組成物 | |
| AU2001264806A1 (en) | Stable liquid and solid formulations | |
| CA2182952A1 (fr) | Procede d'administration de benzamides ou de phenothiazines a substitution n | |
| DE102004040630A1 (de) | Kombinationstherapie mit Procain | |
| JPS63201125A (ja) | 胃十二指腸潰瘍の治療に対する相乗的抗分泌作用を有する薬剤組成物 |